How Much Does Medication treatment for multiple sclerosis Cost in Republic of Korea?
Medication treatment for multiple sclerosis in the Republic of Korea typically costs from $2,200 to $6,000. Total expenses depend on the hospital tier, chosen therapeutic approach, and diagnostic requirements. In the US, this procedure costs $19,500 on average. Major medical hubs include Seoul, Incheon, and Goyang, where clinics often provide comprehensive neurological care.
- Ocrevus (ocrelizumab). $8,500 to $14,000 for infusion-based disease-modifying therapy.
- Diagnostics and MRI. Comprehensive testing and brain imaging with contrast typically add $1,900 to $3,700.
- Hospital tier variations. Tertiary university centers in Seoul often charge 15–20% more than regional clinics.
- Oral medications. First-line disease-modifying therapies often serve as a lower-cost entry point for management.
Bookimed Expert Insight. Seoul National University Hospital and Severance Hospital attract international patients by matching US-level outcomes. SNUH reports a 90% success rate in Gamma Knife procedures for related neurological conditions. Patients should prioritize hospitals accredited by Joint Commission International (JCI). Severance Hospital offers specialized care under board-certified neurologists like Kim Seung Min. Digital infrastructure at SNUBH further ensures treatment precision.
| Republic of Korea | Turkey | Austria | |
|---|---|---|---|
| Medication treatment for multiple sclerosis | ≈ $2,200 | from $2,500 | ≈ $10,500 |
| Ocrevus (ocrelizumab) | ≈ $8,500 | ≈ $4,500 | ≈ $8,800 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Medication treatment for multiple sclerosis upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Medication treatment for multiple sclerosis and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Medication treatment for multiple sclerosis journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Medication treatment for multiple sclerosis Clinics in Republic of Korea: 5 Verified Options and Prices
Medication treatment for multiple sclerosis Overview in Republic of Korea
Day 1
- Arrive in the country.
- Check into your hotel (accommodation not included).
- Rest and acclimatize to the new environment.
Day 2
- Undergo a regular transfer to the clinic.
- Have your first consultation with a hematologist.
- Undergo necessary medical tests.
Day 3
- Revisit the hematologist with test results.
- Begin medication treatment for multiple sclerosis.
Day 4 to Day 14
- Continue the medication treatment as prescribed.
- Regular follow-ups with the hematologist.
- Monitor for any side effects or improvements.
Week 3
- Assess the effectiveness of the medication.
- Adjustment of treatment plan if necessary.
Week 4
- Continue with adjusted treatment plan if any.
- Final consultation with the hematologist.
Week 5
- Discharge from the clinic.
- Return home with a continuation plan for medication.
Note: Each patient"s journey with multiple sclerosis differs. This plan is a general guideline and may be adjusted based on individual needs.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Han Yeongmin
Dr. Han Yeongmin is a neurosurgeon (MD, PhD). He is Medical Director and Director of the Neurosurgery Center at Incheon St. Mary’s Hospital. He treats cerebrovascular disease and peripheral nerve disorders. He also specializes in brain tumors and skull base surgery. Conditions include stroke, cerebral hemorrhage, cerebral infarction, and moyamoya disease. He performs PEN, PNP, and SNB. He also offers microscopic and endoscopic discectomy, artificial disc replacement, MIS-TLIF/minimally invasive spinal fusion, and vertebroplasty.
He earned his MD and PhD from The Catholic University of Korea. He served as a visiting professor in cerebrovascular and skull base surgery at Barrow Neurological Institute (Phoenix, Arizona, USA). He also served at Harborview Medical Center, University of Washington (Seattle, USA).
His publications include co-authorship of Chapter 52 of the Textbook of Korean Cerebrovascular Surgery. He also co-authored Acoustic Neuroma Oncology. He is a full member of KNS, KSCVS, KSBS, KBTS, KNTS, KSNS, and KSPNS.

Kim Seung Min
Dr. Kim Seung Min is a neurologist specializing in medication treatment for multiple sclerosis at Severance Hospital.
- Focuses on personalized treatment plans for MS patients
- Works at Severance Hospital – a leading neurology center
- Dedicated to staying updated with latest MS treatment protocols

Kyoung Heo
The doctor is a leading neurologist in South Korea, specializing in epilepsy treatment. Currently, the doctor serves as the Head of the Neurology Department at Yonsei Severance Hospital.
The doctor graduated from Yonsei University College of Medicine and is an active member of several professional organizations, including The Korean Epilepsy Society, The Korean Neurological Association, and The Korea Medical Association.

Dong Hyeon Lee
Dr. Dong Hyeon Lee is a hematologist-oncologist at Ewha Womans University Medical Center in Seoul. He specializes in bone marrow transplantation, including alternate donor and mismatched transplants. Dr. Lee treats colon cancer, myeloma, and lymphoma. He is a member of multiple professional oncology societies.
- Holds a Ph.D. from Sungkyunkwan University College of Medicine.
- Performs bone marrow transplants for complex hematological conditions.
- Authored over 10 peer-reviewed research papers in oncology.
- Works at a JCI-accredited hospital ranked among the world's best by Newsweek.
Video Stories from Bookimed Patients
Share this content
Anna Leonova
FAQ about Medication treatment for multiple sclerosis in Republic of Korea
Is medication treatment for multiple sclerosis covered by Korean national insurance?
South Korea National Health Insurance Service (NHIS) covers multiple sclerosis (MS) medication through a positive listing system based on clinical utility. Patients often qualify for the rare intractable disease designation, reducing standard 30% co-payments to 10% for approved disease-modifying therapies at Joint Commission International-accredited Seoul hospitals.
- Coverage rate: Established disease-modifying therapies typically receive 70% to 90% reimbursement under NHIS protocols.
- High-efficacy drugs: Ocrevus (ocrelizumab) is now reimbursed for relapsing-remitting and secondary progressive MS cases.
- Safety net: The NHIS ceiling system caps annual out-of-pocket costs based on patient income levels.
- Access criteria: Coverage for second-line treatments usually requires documented failure of first-line interferon therapies.
Bookimed Expert Insight: While major centers like Severance Hospital and Seoul National University Hospital offer advanced care, international patients should note that newer monoclonal antibodies often carry a high upfront deductible. Data shows that starting treatment at a university-affiliated clinic facilitates faster access to the rare disease designation, which is crucial for reducing monthly medication costs from $3,000 to approximately $300.
Patient Consensus: Patients emphasize securing the rare intractable disease status early via a neurologist to maximize benefits. They also caution that switching to newer medications can lead to temporary self-pay periods while waiting for hospital committee approvals.
What is the standard procedure to start MS treatment in Korea?
Starting MS treatment in Korea requires a formal diagnosis at a tertiary hospital using the 2017 McDonald Criteria. Patients must undergo brain and spinal MRI with contrast, evoked potentials, and lumbar punctures. Foreigners with existing diagnoses usually require local re-evaluation by Korean neurologists to access the national subsidy system.
- Tertiary centers: Diagnosis occurs at major facilities like Seoul National University Hospital or Severance Hospital.
- Rare disease registration: Physicians must register patients under the V085 code for 90% cost coverage.
- Stepped therapy: Treatment begins with first-line injectables like Interferon-beta or oral Teriflunomide medications.
- Escalation protocol: Moving to high-efficacy drugs like Ocrevus requires documented clinical relapses or MRI activity.
Bookimed Expert Insight: While top-tier facilities like Severance Hospital and SNUH serve millions, wait times for initial MS diagnostics can reach 3 months. Patients seeking faster access to high-efficacy therapies like Ocrelizumab should meticulously document every relapse. High-volume centers prioritize this evidence when petitioning the Health Insurance Review and Assessment Service for second-line drug approvals.
Patient Consensus: Patients emphasize budget planning for 3 to 6 months of out-of-pocket costs if starting high-efficacy treatments before insurance pre-approval. They recommend joining local support groups to access specific appeal templates for better medication coverage.
Are there any newer therapies or clinical trials available in Korea for multiple sclerosis?
Multiple sclerosis patients in Korea specifically benefit from the 2024 approval of Ocrevus (ocrelizumab). This therapy targets relapsing and primary progressive MS forms. Major Seoul institutions currently conduct phase 3 clinical trials for BTK inhibitors and advanced mesenchymal stem cell therapies for neuroregeneration.
- Ocrevus availability: Intravenous formulation is available at centers like Seoul National University Hospital.
- BTK inhibitor trials: Active phase 3 studies include Tolebrutinib and Fenebrutinib for secondary progression.
- Stem cell research: Specialized programs at Yonsei Severance Hospital offer autologous and mesenchymal cell treatments.
- Emerging delivery: Subcutaneous Ocrevus injections are undergoing final regulatory review to reduce treatment time.
Bookimed Expert Insight: Korea’s clinical trial landscape is exceptionally centralized in Seoul. Hospitals like Seoul National University Hospital and Severance Hospital manage millions of patients annually. This high volume accelerates recruitment for global trials. Patients often access BTK inhibitors here years before general market release.
Patient Consensus: Patients value the rapid integration of global drugs into the national reimbursement system. Many appreciate the digital efficiency of Seoul’s `smart hospitals` which streamlines long-term monitoring and follow-up care.
Is rediagnosis mandatory for foreign patients who already carry an MS diagnosis?
Rediagnosis in the Republic of Korea is generally required to access local treatment and prescription medication. While Korean neurologists recognize the global McDonald criteria, major academic centers in Seoul typically perform independent evaluations including new MRIs and lumbar punctures to establish a clinical baseline and satisfy strict national health insurance protocols.
- Diagnostic verification: Major hospitals usually repeat MRIs and laboratory tests to ensure local clinical accuracy.
- Medication access: Korean health insurance requires domestic confirmation before approving high-cost disease-modifying therapies like Ocrevus.
- Timeline impact: The internal rediagnosis process often adds 2 to 6 weeks before starting treatment.
- Documentation needs: Patients must provide original imaging CDs and raw lab data, not just summaries.
Bookimed Expert Insight: Data from leading Seoul institutions like Severance Hospital and Seoul National University Hospital shows a strict adherence to digitalized internal records. While these hospitals are world-class—with Severance managing 1.6 million outpatients annually—they rarely skip local diagnostics. To save time, choose a digital-first clinic like SNUBH which uses AI imaging to potentially speed up the comparison of your old scans with new results.
Patient Consensus: Patients report that while translating foreign neurology reports is helpful, major Seoul hospitals still insist on redoing tests. Many recommend contacting the hospital before traveling to confirm if they will accept original digital imaging files.
















